Resilience is a biotechnology company that develops and commercializes therapies for patients with rare diseases. The company's lead product candidate, RSLV-132, is a treatment for congenital adrenal hyperplasia, a rare genetic disorder that affects the adrenal glands. Resilience was founded in 2020 by a group of biotech industry veterans, including Rahul Singhvi, Kathryn Phillips, and Juan Harrison. The company has raised over $800 million in funding from investors such as ARCH Venture Partners and 8VC.